164 related articles for article (PubMed ID: 36647005)
1. Experimental analysis of bladder cancer-associated mutations in EP300 identifies EP300-R1627W as a driver mutation.
Luo M; Zhang Y; Xu Z; Lv S; Wei Q; Dang Q
Mol Med; 2023 Jan; 29(1):7. PubMed ID: 36647005
[TBL] [Abstract][Full Text] [Related]
2. EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients.
Zhu G; Pei L; Li Y; Gou X
Aging (Albany NY); 2020 Feb; 12(3):2132-2141. PubMed ID: 32012118
[TBL] [Abstract][Full Text] [Related]
3. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
Ring A; Kaur P; Lang JE
BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
[TBL] [Abstract][Full Text] [Related]
4. Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder.
Boorjian SA; Heemers HV; Frank I; Farmer SA; Schmidt LJ; Sebo TJ; Tindall DJ
Endocr Relat Cancer; 2009 Mar; 16(1):123-37. PubMed ID: 18845648
[TBL] [Abstract][Full Text] [Related]
5. Frameshift mutations of tumor suppressor gene EP300 in gastric and colorectal cancers with high microsatellite instability.
Kim MS; Lee SH; Yoo NJ; Lee SH
Hum Pathol; 2013 Oct; 44(10):2064-70. PubMed ID: 23759652
[TBL] [Abstract][Full Text] [Related]
6. Functional Impact of Chromatin Remodeling Gene Mutations and Predictive Signature for Therapeutic Response in Bladder Cancer.
Duex JE; Swain KE; Dancik GM; Paucek RD; Owens C; Churchill MEA; Theodorescu D
Mol Cancer Res; 2018 Jan; 16(1):69-77. PubMed ID: 28970362
[TBL] [Abstract][Full Text] [Related]
7. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder.
Gui Y; Guo G; Huang Y; Hu X; Tang A; Gao S; Wu R; Chen C; Li X; Zhou L; He M; Li Z; Sun X; Jia W; Chen J; Yang S; Zhou F; Zhao X; Wan S; Ye R; Liang C; Liu Z; Huang P; Liu C; Jiang H; Wang Y; Zheng H; Sun L; Liu X; Jiang Z; Feng D; Chen J; Wu S; Zou J; Zhang Z; Yang R; Zhao J; Xu C; Yin W; Guan Z; Ye J; Zhang H; Li J; Kristiansen K; Nickerson ML; Theodorescu D; Li Y; Zhang X; Li S; Wang J; Yang H; Wang J; Cai Z
Nat Genet; 2011 Aug; 43(9):875-8. PubMed ID: 21822268
[TBL] [Abstract][Full Text] [Related]
8. Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression.
Ogiwara H; Sasaki M; Mitachi T; Oike T; Higuchi S; Tominaga Y; Kohno T
Cancer Discov; 2016 Apr; 6(4):430-45. PubMed ID: 26603525
[TBL] [Abstract][Full Text] [Related]
9. In silico analysis reveals EP300 as a panCancer inhibitor of anti-tumor immune response via metabolic modulation.
Krupar R; Watermann C; Idel C; Ribbat-Idel J; Offermann A; Pasternack H; Kirfel J; Sikora AG; Perner S
Sci Rep; 2020 Jun; 10(1):9389. PubMed ID: 32523042
[TBL] [Abstract][Full Text] [Related]
10. EP300 as a Molecular Integrator of Fibrotic Transcriptional Programs.
Rubio K; Molina-Herrera A; Pérez-González A; Hernández-Galdámez HV; Piña-Vázquez C; Araujo-Ramos T; Singh I
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569677
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of MIR9‑3HG inhibits proliferation and promotes apoptosis of cervical cancer cells by miR‑498 via EP300.
Li F; Liang Y; Ying P
Mol Med Rep; 2021 Nov; 24(5):. PubMed ID: 34468010
[TBL] [Abstract][Full Text] [Related]
12. Expression and Prognostic Significance of
Godlewski J; Krazinski BE; Kowalczyk AE; Kiewisz J; Kiezun J; Kwiatkowski P; Sliwińska-Jewsiewicka A; Wierzbicki PW; Kmieć Z
Anticancer Res; 2017 Jun; 37(6):2927-2937. PubMed ID: 28551630
[TBL] [Abstract][Full Text] [Related]
13. CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis.
Huang YH; Cai K; Xu PP; Wang L; Huang CX; Fang Y; Cheng S; Sun XJ; Liu F; Huang JY; Ji MM; Zhao WL
Signal Transduct Target Ther; 2021 Jan; 6(1):10. PubMed ID: 33431788
[TBL] [Abstract][Full Text] [Related]
14. Somatic EP300-G211S mutations are associated with overall somatic mutational patterns and breast cancer specific survival in triple-negative breast cancer.
Bemanian V; Noone JC; Sauer T; Touma J; Vetvik K; Søderberg-Naucler C; Lindstrøm JC; Bukholm IR; Kristensen VN; Geisler J
Breast Cancer Res Treat; 2018 Nov; 172(2):339-351. PubMed ID: 30132219
[TBL] [Abstract][Full Text] [Related]
15. Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers.
Sarkar S; Jülicher KP; Burger MS; Della Valle V; Larsen CJ; Yeager TR; Grossman TB; Nickells RW; Protzel C; Jarrard DF; Reznikoff CA
Cancer Res; 2000 Jul; 60(14):3862-71. PubMed ID: 10919661
[TBL] [Abstract][Full Text] [Related]
16. Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP.
Qian M; Zhang H; Kham SK; Liu S; Jiang C; Zhao X; Lu Y; Goodings C; Lin TN; Zhang R; Moriyama T; Yin Z; Li Z; Quah TC; Ariffin H; Tan AM; Shen S; Bhojwani D; Hu S; Chen S; Zheng H; Pui CH; Yeoh AE; Yang JJ
Genome Res; 2017 Feb; 27(2):185-195. PubMed ID: 27903646
[TBL] [Abstract][Full Text] [Related]
17. Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.
Asaduzzaman M; Constantinou S; Min H; Gallon J; Lin ML; Singh P; Raguz S; Ali S; Shousha S; Coombes RC; Lam EW; Hu Y; Yagüe E
Breast Cancer Res Treat; 2017 Jun; 163(3):461-474. PubMed ID: 28341962
[TBL] [Abstract][Full Text] [Related]
18. Lack of somatic mutations in the catalytic domains of CREBBP and EP300 genes implies a role for histone deacetylase inhibition in myeloproliferative neoplasms.
Andersen CL; Hasselbalch H; Grønbæk K
Leuk Res; 2012 Apr; 36(4):485-7. PubMed ID: 22177454
[TBL] [Abstract][Full Text] [Related]
19. Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies.
Scialdone A; Khazaei S; Hasni MS; Lennartsson A; Gullberg U; Drott K
Exp Hematol; 2019 Nov; 79():35-46.e1. PubMed ID: 31669559
[TBL] [Abstract][Full Text] [Related]
20. Importin-11 overexpression promotes the migration, invasion, and progression of bladder cancer associated with the deregulation of CDKN1A and THBS1.
Zhao J; Shi L; Zeng S; Ma C; Xu W; Zhang Z; Liu Q; Zhang P; Sun Y; Xu C
Urol Oncol; 2018 Jun; 36(6):311.e1-311.e13. PubMed ID: 29602637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
